2024
The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART)
Chakrani Z, Patel M, Mellgard G, McCroskery S, Saffran N, Taylor N, Liaw B, Galsky M, Oh W, Tsao C, Ganta T, Patel V. The Association of Statin Use With Survival Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Androgen Receptor Targeted Therapies (ART). Clinical Genitourinary Cancer 2024, 22: 102227. PMID: 39437664, DOI: 10.1016/j.clgc.2024.102227.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAndrogen Receptor AntagonistsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMolecular Targeted TherapyProgression-Free SurvivalProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantReceptors, AndrogenRetrospective StudiesSurvival RateTreatment OutcomeConceptsMetastatic castration-resistant prostate cancerAndrogen receptor-targeted therapiesPSA progression free survivalOverall survivalConcurrent statinSurvival outcomesStatin useSingle-institution retrospective analysis of patientsHazard ratioSingle-institution retrospective analysisCastration-resistant prostate cancerRetrospective analysis of patientsConcurrent statin useAssociation of statin useProgression free survivalReceptor-targeted therapyCox proportional hazards regression modelsOutcomes of patientsAnalysis of patientsMultivariate survival analysisProportional hazards regression modelsTumor cell viabilityMultivariate logistic regressionHazards regression modelsEstimate hazard ratiosGender disparities in utilization of statins for low density lipoprotein management across the spectrum of atherosclerotic cardiovascular disease: Insights from the houston methodist cardiovascular disease learning health system registry
Shahid I, Satish P, Gullapelli R, Nicholas J, Javed Z, Avenatti E, Bose B, Mahajan S, Roy T, Sharma G, Rodriguez F, Andrieni J, Jones S, Al-Kindi S, Cainzos-Achirica M, Nasir K. Gender disparities in utilization of statins for low density lipoprotein management across the spectrum of atherosclerotic cardiovascular disease: Insights from the houston methodist cardiovascular disease learning health system registry. American Journal Of Preventive Cardiology 2024, 19: 100722. PMID: 39281350, PMCID: PMC11402022, DOI: 10.1016/j.ajpc.2024.100722.Peer-Reviewed Original ResearchHigh-intensity statinsRacial/ethnic subgroupsSystem registryStatin utilizationLDL-CHigh-intensity statin useGender disparitiesSocioeconomic risk factorsLDL-C managementUS healthcare systemMultivariate logistic regression analysisLDL-C goalsLDL-C <Utilization of statinsAtherosclerotic cardiovascular diseaseLogistic regression analysisSocioeconomic subgroupsHealthcare systemStatin uptakeStatin useAdult patientsLipid managementLipoprotein managementStatinsSignificant gender disparitySecondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2023
National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020
Lu Y, Liu Y, Dhingra L, Caraballo C, Mahajan S, Massey D, Spatz E, Sharma R, Rodriguez F, Watson K, Masoudi F, Krumholz H. National Trends in Racial and Ethnic Disparities in Use of Recommended Therapies in Adults with Atherosclerotic Cardiovascular Disease, 1999-2020. JAMA Network Open 2023, 6: e2345964. PMID: 38039001, PMCID: PMC10692850, DOI: 10.1001/jamanetworkopen.2023.45964.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHistory of ASCVDCross-sectional studyLifestyle modificationPharmacological medicationsOptimal careCurrent careUS adultsEthnic differencesWhite individualsGuideline-recommended therapiesTotal cholesterol controlNon-Hispanic white individualsNutrition Examination SurveyLatino individualsQuality of careSelf-reported raceStatin useRecommended TherapiesSecondary preventionCholesterol controlOptimal regimensSmoking cessationEligible participantsExamination SurveySimplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology
Brown S, Hamid A, Pederson E, BS A, Maddula R, Goodman R, Lamberg M, Caraballo P, Noseworthy P, Lukan O, Echefu G, Berman G, Choudhuri I. Simplified rules-based tool to facilitate the application of up-to-date management recommendations in cardio-oncology. Cardio-Oncology 2023, 9: 37. PMID: 37891699, PMCID: PMC10605976, DOI: 10.1186/s40959-023-00179-w.Peer-Reviewed Original ResearchCancer survivorsCare suggestionsCare of cancer survivorsScientific statementCardiovascular diseaseExpert consensusCardiovascular disease preventionRisk of cardiovascular diseaseRates of statin usePoint of carePrevent cardiovascular diseaseHealth systemCardiovascular carePrevention recommendationsInadequate utilizationDisease preventionCardiovascular medicationsCareMethodological studySociety recommendationsStatin useGuideline documentsPatient suitabilitySurvivorsConsensus recommendationsStatin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia
Podoltsev N, Wang R, Shallis R, Stempel J, Di M, Neparidze N, Zeidan A, Huntington S, Giri S, Hull S, Gore S, Ma X. Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia. Cancer Medicine 2023, 12: 18889-18900. PMID: 37702132, PMCID: PMC10557879, DOI: 10.1002/cam4.6528.Peer-Reviewed Original ResearchConceptsIncidence of thrombosisPolycythemia veraEssential thrombocythemiaStatin useOlder adultsEnd Results-Medicare databasePopulation-based cohort studyArterial thrombotic eventsSurvival of patientsUse of statinsClaims-based studyRisk of thrombosisCardiovascular morbidityCause mortalityTreatment weighting (IPTW) approachCohort studyOlder patientsOverall survivalThrombotic eventsVenous thrombosisPatient populationPrevious registryStatinsTherapeutic strategiesET subgroupSex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank
Rentsch C, Garfield V, Mathur R, Eastwood S, Smeeth L, Chaturvedi N, Bhaskaran K. Sex-specific risks for cardiovascular disease across the glycaemic spectrum: a population-based cohort study using the UK Biobank. The Lancet Regional Health - Europe 2023, 32: 100693. PMID: 37671124, PMCID: PMC10477037, DOI: 10.1016/j.lanepe.2023.100693.Peer-Reviewed Original ResearchCoronary artery diseaseDeep vein thrombosisSex-specific riskCardiovascular diseaseUndiagnosed diabetesGlycaemic spectrumPulmonary embolismExcess riskPopulation-based cohort studyRisk of CVDAge-adjusted HRIncident cardiovascular diseaseBritish Heart FoundationSex-specific associationsUK BiobankWeight reduction strategiesStatin medicationStatin useClinical characteristicsCohort studyComposite outcomeNormal HbA1cVein thrombosisArtery diseaseHeart failureBaseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials
Balasubramanian P, Kernan W, Sheth K, Ofstad A, Rosenstock J, Wanner C, Zinman B, Mattheus M, Marx N, Inzucchi S. Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials. Stroke 2023, 54: 2013-2021. PMID: 37449424, PMCID: PMC10358436, DOI: 10.1161/strokeaha.122.042053.Peer-Reviewed Original ResearchConceptsCardiovascular risk factor controlRisk factor controlCoronary artery diseaseEMPA-REG OUTCOMECardiovascular outcome trialsType 2 diabetesRisk factorsOutcome trialsBlood pressureOdds ratioAntiplatelet/anticoagulant medicationsAntiplatelet/anticoagulant therapyDiabetes cardiovascular outcome trialsSuboptimal risk factor controlCardiovascular risk factorsRecurrent ischemic eventsDiastolic blood pressureSystolic blood pressureRespective odds ratiosFactor controlCross-sectional analysisLogistic regression modelsMacrovascular complicationsStatin useAnticoagulant medicationUncovering the Relationship Between Statins and Muscle Problems in the ELSA-Brasil MSK Cohort
Pedroso A, Barreto S, Telles R, Machado L, Haueisen Sander Diniz M, Duncan B, Figueiredo R. Uncovering the Relationship Between Statins and Muscle Problems in the ELSA-Brasil MSK Cohort. Cardiovascular Drugs And Therapy 2023, 38: 1409-1414. PMID: 37261675, DOI: 10.1007/s10557-023-07476-7.Peer-Reviewed Original ResearchConceptsFive-times-sit-to-standStatin useMSK cohortMuscle problemsELSA-BrasilMuscle painHandgrip testFive-times-sit-to-stand testDuration of statin treatmentSecondary analysisMultivariate logistic regression analysisBrazilian civil servantsLogistic regression analysisNo significant associationSelf-reported symptomsCross-sectional data analysisStatin treatmentEfficacy-effectiveness gapMuscle strengthHandgrip strengthHighest quintileMuscle groupsMuscle weaknessStatinsPainQuantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients
Kwan J, Arbune A, Henry M, Hu R, Wei W, Nguyen V, Lee S, Lopez-Mattei J, Guha A, Huber S, Bader A, Meadows J, Sinusas A, Mojibian H, Peters D, Lustberg M, Hull S, Baldassarre L. Quantitative cardiovascular magnetic resonance findings and clinical risk factors predict cardiovascular outcomes in breast cancer patients. PLOS ONE 2023, 18: e0286364. PMID: 37252927, PMCID: PMC10228774, DOI: 10.1371/journal.pone.0286364.Peer-Reviewed Original ResearchConceptsBreast cancer patientsSystolic heart failureCardiovascular outcomesCancer patientsHeart failureValvular diseaseStrain abnormalitiesLeft ventricular ejection fraction reductionCancer treatment-related cardiotoxicityCardiovascular magnetic resonance findingsVentricular ejection fraction reductionYale-New Haven HospitalEjection fraction reductionTreatment-related cardiotoxicityAdverse cardiovascular outcomesClinical risk factorsNormal LV functionGlobal longitudinal strainIschemic heart diseaseMagnetic resonance findingsRisk regression modelsNew Haven HospitalSubclinical cardiotoxicityDiastolic dysfunctionStatin usePragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale
Joseph J, Pajewski N, Dolor R, Sellers M, Perdue L, Peeples S, Henrie A, Woolard N, Jones W, Benziger C, Orkaby A, Mixon A, VanWormer J, Shapiro M, Kistler C, Polonsky T, Chatterjee R, Chamberlain A, Forman D, Knowlton K, Gill T, Newby L, Hammill B, Cicek M, Williams N, Decker J, Ou J, Rubinstein J, Choudhary G, Gazmuri R, Schmader K, Roumie C, Vaughan C, Effron M, Cooper‐DeHoff R, Supiano M, Shah R, Whittle J, Hernandez A, Ambrosius W, Williamson J, Alexander K, Group P. Pragmatic evaluation of events and benefits of lipid lowering in older adults (PREVENTABLE): Trial design and rationale. Journal Of The American Geriatrics Society 2023, 71: 1701-1713. PMID: 37082807, PMCID: PMC10258159, DOI: 10.1111/jgs.18312.Peer-Reviewed Original ResearchConceptsOlder adultsHigh-intensity statin therapyRandomized pragmatic clinical trialCognitive testingBenefits of lipidInitiation of statinsBenefits of statinsNational Death Index searchEffect of statinsPragmatic clinical trialsCommunity-dwelling adultsMild cognitive impairmentLow participant burdenBaseline cognitive testingElectronic health recordsCardiovascular deathCardiovascular eventsCoronary revascularizationLipid panelStatin therapyStatin useUnstable anginaHeart failurePrimary outcomeMyocardial infarctionAssociation between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure
Chapin S, Kaplan D, Taddei T, Mahmud N. Association between statin exposure and short-term mortality in patients with high-grade acute-on-chronic liver failure. JHEP Reports 2023, 5: 100740. PMID: 37215188, PMCID: PMC10193237, DOI: 10.1016/j.jhepr.2023.100740.Peer-Reviewed Original ResearchChronic liver failureShort-term mortalityRetrospective cohort studyStatin exposureLiver failureStatin useCohort studyLogistic regression modelsLower oddsHigh short-term mortalityVeterans Health Administration patientsDose exposureMultivariable logistic regression modelClasses of medicationsFuture prospective studiesVeterans Health AdministrationDose-dependent reductionPotential beneficial effectsStatin therapyTerm mortalityAnalytic cohortRegression modelsProspective studyReduced oddsACLF
2022
Primary prevention statin therapy in older adults
Nanna M, Abdullah A, Mortensen M, Navar A. Primary prevention statin therapy in older adults. Current Opinion In Cardiology 2022, 38: 11-20. PMID: 36598445, PMCID: PMC9830552, DOI: 10.1097/hco.0000000000001003.Peer-Reviewed Original ResearchConceptsAge 75Older adult populationStatin treatmentRandomized trialsAdult populationPrimary prevention statin therapyOlder adultsAverage lifespan increasesRecent guideline recommendationsACC/AHAOngoing randomized trialsPrevention of morbidityPaucity of evidenceStatin therapyStatin useUSPSTF recommendationsOlder patientsGuideline recommendationsOngoing trialsTreatment recommendationsCardiovascular diseaseTreatment benefitTreatment decisionsGuidelines conflictTrialsContemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States
Shen M, Nargesi A, Nasir K, Bhatt DL, Khera R. Contemporary National Patterns of Eligibility and Use of Novel Lipid‐Lowering Therapies in the United States. Journal Of The American Heart Association 2022, 11: e026075. PMID: 36102276, PMCID: PMC9683659, DOI: 10.1161/jaha.122.026075.Peer-Reviewed Original ResearchConceptsLipid-lowering therapyIcosapent ethylCardiology/American Heart Association (ACC/AHA) guideline recommendationsNutrition Examination Survey dataAddition of ezetimibeUse of statinsClinical practice guidelinesCurrent statin usePopulation health outcomesConclusions SixCardiovascular outcomesStatin useClinical profileGuideline recommendationsLipid profileNational HealthPCSK9iNovel therapiesNovel agentsPractice guidelinesUS adultsAmerican CollegeStatinsHealth outcomesTherapyStatins and statin intensity in peripheral artery disease.
Sagris M, Katsaros I, Giannopoulos S, Rosenberg RD, Altin SE, Rallidis L, Mena-Hurtado C, Armstrong EJ, Kokkinidis DG. Statins and statin intensity in peripheral artery disease. Vasa 2022, 51: 198-211. PMID: 35673949, DOI: 10.1024/0301-1526/a001012.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsPeripheral artery diseaseLow-intensity statinsLoss of patencyStatin useStatin doseIntensity statinsArtery diseaseFirst-line lipid-lowering therapyAdverse cardiovascular eventsAmputation-free survivalHigher statin doseLipid-lowering therapyMyocardial infarction rateRisk of amputationImpact of statinsStatin intensityCardiovascular eventsPAD patientsCardiovascular deathCardiovascular mortalityCause mortalityInfarction rateIschemia patientsStatin treatmentStatin Usage Increases White Matter Hyperintensities
Goldstein ED, Garg G, Navarro K, Wolcott Z, Yaghi S, Wong KH, McLean K, de Havenon AH. Statin Usage Increases White Matter Hyperintensities. The Neurologist 2022, 28: 94-98. PMID: 35680399, DOI: 10.1097/nrl.0000000000000448.Peer-Reviewed Original ResearchConceptsWhite matter hyperintensitiesWMH progressionStatin usageTop tertileRisk factorsMatter hyperintensitiesWMH volumeConventional cerebrovascular risk factorsProgression of WMHCerebral small vessel diseaseInfluence of dyslipidemiaCerebrovascular risk factorsInfluence of statinsBaseline WMH volumeSmall vessel diseaseSynergistic risk factorsLow-density lipoproteinFull therapyStatin useVessel diseaseStudy visitWMH developmentPartial therapyWMH dataReductase inhibitorsHigh-Intensity Statin Use Among Patients With Atherosclerosis in the U.S.
Nelson AJ, Haynes K, Shambhu S, Eapen Z, Cziraky MJ, Nanna MG, Calvert SB, Gallagher K, Pagidipati NJ, Granger CB. High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S. Journal Of The American College Of Cardiology 2022, 79: 1802-1813. PMID: 35512860, PMCID: PMC9344279, DOI: 10.1016/j.jacc.2022.02.048.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseHigh-intensity statinsStatin useYounger patientsFemale patientsHigh-intensity statin useHigher Charlson comorbidity scoreAppropriate statin useNew guideline recommendationsCharlson comorbidity scoreRetrospective cohort studyPeripheral artery diseaseModerate-intensity statinsMultivariable logistic regressionCommercial health plansMedical claims dataComorbidity scoreIndex dateCohort studyOlder patientsPreventive therapyStatin usersArtery diseaseContemporary cohortGuideline recommendationsCOST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS
Campbell C, Desai N, Electricwala B, Constanti M, Trueman D, Woodcock F, Cristino J. COST-EFFECTIVENESS OF INCLISIRAN IN ATHEROSCLEROTIC CARDIOVASCULAR PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL DESPITE STATIN USE: A THRESHOLD ANALYSIS. Journal Of The American College Of Cardiology 2022, 79: 1559. DOI: 10.1016/s0735-1097(22)02550-5.Peer-Reviewed Original ResearchStatin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort
Mahmud N, Chapin S, Goldberg DS, Reddy KR, Taddei TH, Kaplan DE. Statin exposure is associated with reduced development of acute-on-chronic liver failure in a Veterans Affairs cohort. Journal Of Hepatology 2022, 76: 1100-1108. PMID: 35066085, PMCID: PMC9018495, DOI: 10.1016/j.jhep.2021.12.034.Peer-Reviewed Original ResearchConceptsChronic liver failureStatin exposureLiver failureStatin useCohort studyChronic liver failure developmentInverse probability treatment weightingProportional hazards regression modelsDoses of statinsVeterans Affairs cohortRetrospective cohort studyChronic liver diseaseHazards regression modelsLarge national cohortVeterans Health AdministrationNumerous beneficial effectsMarginal structural modelsMedian followStatin therapyLiver diseaseNational cohortACLFTreatment weightingCirrhosisPatients
2021
PCSK9 Inhibiting Monoclonal Antibodies
Ahmed Z, Juthani P, Lee M, Desai N. PCSK9 Inhibiting Monoclonal Antibodies. Stroke Revisited 2021, 125-133. DOI: 10.1007/978-981-16-3923-4_11.Peer-Reviewed Original ResearchProprotein convertase subtilisin/kexin type 9Lipid-lowering medicationsSubset of patientsIschemic strokeLower PCSK9Low-density lipoprotein cholesterolConvertase subtilisin/kexin type 9Subtilisin/kexin type 9Monoclonal antibodiesCoenzyme A (HMG-CoA) reductase inhibitorsComponents of dyslipidemiaHigh-intensity statinsStroke risk reductionModifiable risk factorsHealthy lifestyle modificationsLDL-C levelsRisk of strokeStatin-induced myopathyTreatment of hyperlipidemiaA Reductase InhibitorsLifestyle modificationStatin useLipoprotein cholesterolPCSK9 inhibitorsStroke outcome
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply